Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients.
作者信息
Baron Frédéric, Efficace Fabio, Cannella Laura, Willemze Roel, Vignetti Marco, Muus Petra, Marie Jean-Pierre, Ferrero Dario, Fazi Paola, La Sala Edoardo, Bourhis Jean-Henri, Fabbiano Francesco, Bosi Alberto, Sborgia Marco, Martinelli Giovanni, Wittnebel Sebastian, Trisolini Silvia, Petti Maria Concetta, Halkes Constantijn J M, van der Velden Walter J F M, de Witte Theo, Amadori Sergio, Zittoun Robert A, Suciu Stefan
机构信息
GIGA-I3 and CHU, University of Liège, Liège, Belgium
Gruppo Italiano Malattie Ematologiche Dell'Adulto GIMEMA, Rome, Rome, Italy.
出版信息
Haematologica. 2020 Jan;105(1):e13-e16. doi: 10.3324/haematol.2019.221333. Epub 2019 May 16.
Abstract
摘要
相似文献
1
Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients.
Haematologica. 2020 Jan;105(1):e13-e16. doi: 10.3324/haematol.2019.221333. Epub 2019 May 16.
2
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
N Engl J Med. 1995 Jan 26;332(4):217-23. doi: 10.1056/NEJM199501263320403.
3
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.
N Engl J Med. 1998 Dec 3;339(23):1649-56. doi: 10.1056/NEJM199812033392301.
4
Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for de novo acute myeloid leukemia.
Eur J Haematol. 1997 Apr;58(4):233-40. doi: 10.1111/j.1600-0609.1997.tb01660.x.
5
A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission.
Blood. 2001 Jan 1;97(1):56-62. doi: 10.1182/blood.v97.1.56.
6
7
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.
Blood. 2001 Oct 15;98(8):2326-31. doi: 10.1182/blood.v98.8.2326.
8
Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Childrens Cancer Group pilot study.
J Clin Oncol. 1993 Aug;11(8):1448-57. doi: 10.1200/JCO.1993.11.8.1448.
9
10
Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995).
Leuk Lymphoma. 2005 Jan;46(1):55-61. doi: 10.1080/10428190412331283288.
引用本文的文献
1
Comparison of autologous hematopoietic cell transplantation, matched sibling donor hematopoietic cell transplantation, and chemotherapy in patients with favorable- and intermediate-risk acute myeloid leukemia.
Front Immunol. 2025 Jan 8;15:1511057. doi: 10.3389/fimmu.2024.1511057. eCollection 2024.
2
Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
Bone Marrow Transplant. 2023 Nov;58(11):1197-1202. doi: 10.1038/s41409-023-02075-4. Epub 2023 Aug 8.
3
Overall Survival Rate in Allogeneic Stem Cell Transplanted Patients Requiring Intensive Care Can Be Predicted by the Prognostic Index for Critically Ill Allogeneic Transplantation Patients (PICAT) and the Sequential Organ Failure Assessment (SOFA) Scores.
Cancers (Basel). 2022 Aug 31;14(17):4266. doi: 10.3390/cancers14174266.
4
Haploidentical Stem Cell Transplantation for Acute Myeloid Leukemia: Current Therapies, Challenges and Future Prospective.
Front Oncol. 2021 Oct 28;11:758512. doi: 10.3389/fonc.2021.758512. eCollection 2021.
5
Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients.
J Hematol Oncol. 2021 Oct 24;14(1):174. doi: 10.1186/s13045-021-01190-3.
6
Comparison of post-remission strategies in acute myeloid leukemia: Autologous hematopoietic stem cell transplantation consolidation chemotherapy.
Hematol Rep. 2020 Dec 2;12(3):8380. doi: 10.4081/hr.2020.8380.
7
Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials.
Cancers (Basel). 2020 Nov 11;12(11):3334. doi: 10.3390/cancers12113334.
8
Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT.
Bone Marrow Transplant. 2021 Feb;56(2):461-469. doi: 10.1038/s41409-020-01051-6. Epub 2020 Sep 4.
本文引用的文献
1
Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT.
Am J Hematol. 2018 Dec;93(12):1532-1542. doi: 10.1002/ajh.25285. Epub 2018 Oct 26.
2
Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMT.
Am J Hematol. 2018 Jul;93(7):859-866. doi: 10.1002/ajh.25105. Epub 2018 Apr 28.
3
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12.
4
Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission.
Am J Hematol. 2017 Dec;92(12):1318-1323. doi: 10.1002/ajh.24904. Epub 2017 Sep 28.
5
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.
6
Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.
Leukemia. 2017 Jan;31(1):26-33. doi: 10.1038/leu.2016.183. Epub 2016 Jun 24.
7
Hematopoietic stem cell transplantation for patients with AML in first complete remission.
Blood. 2016 Jan 7;127(1):62-70. doi: 10.1182/blood-2015-07-604546. Epub 2015 Dec 10.
8
High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT.
Bone Marrow Transplant. 2015 Mar;50(3):341-7. doi: 10.1038/bmt.2014.262. Epub 2014 Nov 17.
9
Autologous peripheral blood stem cell transplantation for acute myeloid leukemia.
Blood. 2011 Dec 1;118(23):6037-42. doi: 10.1182/blood-2011-07-370247. Epub 2011 Sep 27.
10
Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.
J Clin Oncol. 2011 Jun 1;29(16):2230-9. doi: 10.1200/JCO.2010.33.7212. Epub 2011 Apr 4.
Zotero 插件